text:
Resverlogix Corp. (T:RVX)
Business Focus: Bio Therapeutic Drugs
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton. The trial will evaluate the safety and...
Resverlogix: The Future of Drug Development, CEO Clip Video
Vancouver, British Columbia--(Newsfile Corp. - December 16, 2021) - Resverlogix Corp. (TSX: RVX) - Donald McCaffrey, President & CEO speaks about the late-stage biotechnology company and their flagship drug - Apabetalone.
Resverlogix Announces Corporate Update Webcast and Conference Call
Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that they will be hosting a corporate update webcast and conference call on Thursday, December 16th, 2021 at 2:00 pm MST. Webcast link:...
Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment
Zenith Capital Corp. ("Zenith" or the "Company") announced today that Zenith Epigenetics Ltd. ("Zenith Epigenetics"), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara Biopharma Co., Ltd. ("Newsoara")...
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients
Resverlogix Corp. ("Resverlogix" or the Company") (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that it has entered into a cooperation agreement with the Supreme Council of the Arab-African Economy which...
Resverlogix In Active Discussions With The Kingdom of Morocco's Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that it is in active discussions with the Kingdom of Morocco's Ministry of Health for possible Phase 2...
Resverlogix to Participate in Leading Scientific Conferences
Resverlogix Corp. ("Resverlogix" or the Company") (TSX: RVX), a world leader in epigenetics or gene regulation, today announces its virtual participation at the following scientific conferences: American Society of Nephrology – Kidney Week 2021...
Resverlogix to Present at Upcoming Conferences
Resverlogix Corp. ("Resverlogix" or the Company") (TSX: RVX), a world leader in epigenetics or gene regulation, announces today that President and CEO Donald McCaffrey will be presenting virtually at the following conferences: 14th Annual LD Micro...
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), today announces the approval of its COVID-19 clinical trial of apabetalone by the Health Research Ethics Board (HREB) – Biomedical Panel at the University of Alberta. This approval...
Study Demonstrates Resverlogix's Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), a world leader in epigenetics, or gene regulation, announces today new data that demonstrates their first-in-class oral small molecule BET inhibitor candidate Apabetalone significantly...
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), a world leader in epigenetics, or gene regulation, today announces that its investigational epigenetic therapeutic apabetalone met the primary endpoint in an investigator led pulmonary...
Resverlogix Announces Management Change
Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that Ken Lebioda is stepping down as Senior Vice President, Business and Corporate Development, effective immediately. "We would like to thank Ken for his important contributions over many...
Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer
Zenith Capital Corp. ("Zenith" or the "Company"), a clinical stage pharmaceutical company focused on the development of novel epigenetic combination therapies for the treatment of cancers, announces the publication of an important study which has...
Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders
Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected six (6) Board...
Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada
Resverlogix Corp. ("Resverlogix") (TSX:RVX) and EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today announced a partnership to support planned commercialization of apabetalone in the United...
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.
Calgary, Alberta--(Newsfile Corp. - May 21, 2021) - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") announces that on May 13, 2021, it acquired 10% secured convertible debentures due May 13, 2022, of Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) (the "Company") in the principal amount of US$6 million and 300,000 common share purchase warrants of the Company by way of a private placement (the "Private Placement") for a purchase price of US$6 million (Cdn$7.4 million).
Resverlogix Announces US$6 Million Debenture Financing
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that it has entered into an investment agreement with a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") which provides for Hepalink to...
Resverlogix's Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: "Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes...
Zenith Epigenetics Announces Clinical Collaboration with Astellas
Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a clinical stage biotechnology company focused on the development of novel epigenetic combination therapies for the treatment of cancers, announces it has entered into an agreement with Astellas...
Apabetalone's Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines
Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of an article titled: "Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro", in...
Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it has successfully received its desired "No Objection Letter" from Health Canada. It has approved the COVID-19 Clinical Trial Application for apabetalone. The planned Phase 2...
Apabetalone's Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell
Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of an article, titled: "BET Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection", in Cell, a high-impact scientific journal. This comes...
Apabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells
Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of a new article titled: "Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro", on...
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck's Immune Check Point Inhibitor KEYTRUDA
Zenith Epigenetics Ltd. ("Zenith" or the "Company") announced today the dosing of first patient with a triple combination of ZEN-3694 + Merck's immune check point inhibitor, KEYTRUDA, + Pfizer's androgen receptor signaling inhibitor (ARSI), XTANDI,...
Resverlogix Announces Change in Fiscal Year-End to December 31
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announces that it is changing its fiscal year-end to December 31, from its current fiscal year-end of April 30. The notice for the year-end change required under National Instrument...
New Published Evidence of Apabetalone's Beneficial Effects on COVID-19
Resverlogix Corp. ("Resverlogix") (TSX:RVX) and QIMR Berghofer Medical Research Institute ("QIMR Berghofer"), one of Australia's most successful medical research institutes, announced today the publishing of a new article providing evidence of...
Resverlogix Reschedules Update Webcast and Conference Call
Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) announces that it has postponed the webcast and conference call, previously scheduled for January 28th, 2021, by one week to February 4th, 2021 at 10:00 am MT. This will allow the...
Resverlogix Announces Update Webcast and Conference Call
Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX:RVX) today announced that on January 28th, 2021 at 10:00 am MT, it will be hosting a webcast and conference call for the purpose of updating stakeholders regarding three key areas:...
Apabetalone's Positive Effect on Hospitalized Patients Involving Heart Failure
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: "Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis...
Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen
Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected six (6) Board members...
Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19) Exposure Significantly Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce recent published findings in the high-impact journal, Proceedings of the National Academy of Sciences (PNAS), that further supports other 2020 publications and...
Resverlogix Files Notice of Annual and Special Meeting of Shareholders
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the filing on SEDAR (www.sedar.com) of the Notice of Meeting and Management Information Circular (the "Notice") related to its Annual and Special Meeting of Shareholders...
Zenith Files Notice of Annual and Special Meeting of Shareholders
Zenith Capital Corp. ("Zenith" or the "Company") today announces the filing on SEDAR (www.sedar.com) of the Notice of Meeting and Management Information Circular (the "Notice") related to its Annual and Special Meeting of Shareholders (the...
Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: "BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with...
Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce today highly significant findings on synergy on improved renal function, as measured by estimated glomerular filtration rate (eGFR), and glucose control, as...
Zenith Confirms Interim Filings on SEDAR
Zenith Capital Corp. ("Zenith" or the "Company") today announces that, further to its October 9, 2020 press release, it today has filed its interim financial statements and related MD&A for the three months ended July 31, 2020 (the "Interim...
A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that its late-stage clinical candidate, apabetalone, has been prominently featured in a recent article, titled: "Protein-driven mechanism of multiorgan damage in...
Resverlogix Announces Presentations at Leading Scientific Conferences
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today its participation during the following leading scientific conferences: American Society of Nephrology (ASN) Kidney Week Reimagined 2020, 13th Clinical Trials on...
Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that Vision Leader Limited, a wholly-owned subsidiary of ORI Star Fund LP ("ORI"), has delivered a notice of conversion to convert its entire September 2019 debenture and...
Zenith Provides Update Regarding Extension of its Filing Calendar
Zenith Capital Corp. ("Zenith" or the "Company") today announces that it has filed its annual financial statements for the year ended April 30, 2020 and related management's discussion and analysis pursuant to National Instrument 51-102...
Resverlogix Announces $13 Million Private Placement
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has entered into a definitive stock purchase agreement for a private placement of 10,560,000 equity units at a price of $1.25 per unit for gross proceeds of $13.2...
Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications
Zenith Epigenetics Ltd. ("Zenith" or the "Company") announced today the execution of a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to develop ZEN-3694 for multiple oncology indications. For the...
Resverlogix Confirms Interim Filings on SEDAR
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that, further to its September 25, 2020 press release, it today has filed its interim financial statements and related MD&A for the three months ended July 31, 2020 (the...
Resverlogix Provides Update Regarding Extension of its Filing Calendar
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that further to its September 11, 2020 press release, it continues to expect to file its interim financial statements and related MD&A for the three months ended July 31, 2020...
Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: "Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases", in the peer-reviewed Medicinal...
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it has filed its annual financial statements for the year ended April 30, 2020, related MD&A and annual information form pursuant to National Instrument 51-102...
Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum ("GCFF") Virtual Conference 2020 – Investing in Innovation
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces its participation at the GCFF Virtual Conference 2020 - Investing in Innovation ("GCFF Virtual Conference") on September 10, 2020. Donald McCaffrey, the Company's President and...
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that, further to its July 28, 2020 press release, it continues to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit...
Zenith Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption
Zenith Capital Corp. ("Zenith" or the "Company") today announces that it intends to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to extend the filing deadline of certain...
Resverlogix Announces Private Placement
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of 3,573,333 equity units at a price of $0.75 per unit for gross proceeds of approximately $2.7 million (US$2.0 million). Each unit was...
Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today the recent publication of an article titled: "Epigenetic modulation by apabetalone counters cytokine driven acute phase response in vitro, in mice and in...
Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs
Zenith Epigenetics Ltd. ("Zenith" or the "Company") announced today significant clinical advances of ZEN-3694, the Company's lead therapeutic compound being developed for epigenetic combination therapies in multiple oncology indications. "Merck,...
Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it intends to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to extend the filing deadline of...
Resverlogix Secures One-Year Extension of Maturity Date of Debenture
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed a one-year extension of the maturity date of its debenture. Mr. Donald McCaffrey, President and CEO stated, "We are very pleased that the debenture has...
Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that the U.S. Food & Drug Administration (FDA) has accepted its BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing...
Zenith Announces Corporate Update Conference Call & Webcast on June 18, 2020 and US$5 Million Equity Investment
Zenith Capital Corp. ("Zenith" or the "Company") today announces it will be hosting a corporate update via conference call and webcast on Thursday, June 18, 2020 at 9:00 am MT / 11:00 am ET. Mr. Donald McCaffrey, President and Chief Executive...
Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress
Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce key data from its BETonMACE clinical trial in pre-specified stage 3 chronic kidney disease (CKD) patients. This data was presented in a virtual oral plenary session at the 57th...
Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the Company will host a Corporate Update Conference Call and Webcast on June 10th, 2020 at 9 am MT/11 am ET. The Company also announces its participation at the...
Resverlogix Plans COVID-19 Clinical Trial Program Launch
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that it is moving forward with a plan to further evaluate apabetalone's impact on COVID-19 in both a preclinical and clinical setting. A first step will be to...
Resverlogix Announces Participation at the American College of Cardiology Scientific Sessions together with the World Congress of Cardiology Virtual
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today its participation at the American College of Cardiology Scientific Sessions, together with the World Congress of Cardiology (ACC.20/WCC), presenting two virtual posters...
Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: "Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary...
Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce a March 23, 2020 bioRxiv publication that has shown apabetalone to inhibit specialized proteins – called bromodomain and extraterminal domain (BET) proteins – from...
Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research
Resverlogix Corp. ("Resverlogix") (TSX: RVX) announces that it is seeking to collaborate with organizations currently testing therapies for SARS-CoV-2 (the virus responsible for COVID-19) in pre-clinical or clinical models. Apabetalone prevents...
Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce the U.S. Food & Drug Administration ("FDA") has granted Breakthrough Therapy Designation for apabetalone in combination with top standard of care, including...
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce today additional highly significant findings and clear synergy when apabetalone is combined with anti-diabetic therapies, including dipeptidyl peptidase 4...
Resverlogix Appoints Dicky To to its Board of Directors
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced that Mr. Dicky To has been appointed to the Company's Board of Directors. His appointment is effective as of December 19, 2019. Dicky is a partner of ORI Capital and...
Zenith Epigenetics Announces Clinical Advancement of ZEN-3694
Zenith Epigenetics Ltd. ("Zenith" or the "Company") announced today the significant clinical advances of ZEN-3694, the Company's lead compound being developed for epigenetic combination therapies in oncology. "I am very pleased to report these...
Resverlogix Announces Change to its Board of Directors
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced that Dr. Eldon Smith has stepped down from the Board of Directors, effective today. "We would like to thank Eldon for his many years of service and wish him all the...
Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) reminds stakeholders that the Company will hold a conference call and webcast on December 6th at 8:30 am ET to supplement the presentation of prespecified BETonMACE cognition results to...
Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that data on apabetalone – and its therapeutic potential for cardiovascular patients experiencing cognitive decline – and the BETonMACE prespecified cognition assessment...
Resverlogix Announces Warrant Exercise Incentive Program
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announces a warrant exercise incentive program ("Incentive Program") designed to encourage the early exercise of 15,593,428 warrants to purchase common shares of the Company. The...
Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that it has scheduled a conference call and webcast to supplement the presentation of BETonMACE results to be made during the American Heart Association's ("AHA") annual...
Resverlogix Announces Voting Results from the 2019 Annual Meeting of Shareholders
Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. A total of 66,053,596 shares (approximately 31.54% of outstanding common shares) were represented...
Zenith Announces Voting Results from the 2019 Annual and Special Meeting of Shareholders
Zenith Capital Corp. ("Zenith" or the "Company") announces that, at its annual and special meeting of shareholders held earlier today, Zenith shareholders approved all resolutions outlined in the Notice of Meeting and Management Information...
Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that BETonMACE did not meet the primary endpoint – reduction in major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction and...
Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that it has issued a 10% secured convertible debenture in the principal amount of US$12 million (the "Debenture") to a wholly-owned subsidiary of ORI Star Fund LP ("ORI"...
Resverlogix to Host BETonMACE Webcast and Conference Call
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that, in connection with BETonMACE topline results, expected to be announced on September 30, 2019, the company plans to hold a webcast and conference call that same...
Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association's Scientific Sessions 2019
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the Late Breaking Science submission, regarding the primary results of the BETonMACE trial, has been accepted by the American Heart Association ("AHA") for presentation...
Resverlogix Provides Update on BETonMACE Phase 3 Trial
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that, following the completion of final patient safety visits (as reported by the Company on July 8, 2019), the resolution of all outstanding queries is expected within a...
Resverlogix Announces Annual and Special Meeting of Shareholders
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that its Annual and Special Meeting of Shareholders (the "Meeting") is to be held Thursday, October 31, 2019 at Mount Royal University, Roderick Mah Centre for Continuous...
Zenith Announces Annual and Special Meeting of Shareholders
Zenith Capital Corp. ("Zenith") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") is to be held Thursday, October 31, 2019 at Mount Royal University, Roderick Mah Centre for Continuous Learning – Ross Glen Hall...
Resverlogix to Present at the European Society of Cardiology's ESC Congress 2019
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces today that it will present at ESC Congress 2019, held this year in Paris, France, from August 31 to September 4, 2019, the world's largest cardiovascular conference. As detailed...
Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694
Zenith Capital Corp. ("Zenith") announced today that Zenith Epigenetics Ltd. ("Zenith Epigenetics" or the "Company"), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara BioPharma Co., Ltd. ("Newsoara")...
Resverlogix Announces Loan Reduction and Extension
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that it has entered into an amending agreement with Third Eye Capital (acting as agent for a syndicate of lenders) to extend the maturity date of the Company's senior...
Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: "Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism" in...
Resverlogix's BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company's event-based, phase 3 registration trial, recently completed their final, follow-up safety visits, marking...
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the first patient in a Phase 1b/2 clinical trial undertaken in collaboration with Pfizer Inc. ("Pfizer"). The...
Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company's event-based, phase 3 registration trial, recently completed their last study visits on treatment. Final,...
Resverlogix Announces Participation at Leading, International Scientific Conferences
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading, international scientific conferences including: the American Diabetes Association's (ADA) 79th Scientific Sessions 2019, the 56th European...
IIROC Trade Resumption - RVX.WT.A
TORONTO, June 7, 2019 /CNW/ - Trading resumes in:
Resverlogix Announces Closing of $15 Million Offering
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has closed its previously announced offering (the "Offering") of units of the Company (the "Units"). An aggregate of approximately 3.8 million Units...
IIROC Trading Halt - RVX.WT.A
TORONTO, June 7, 2019 /CNW/ - The following issues have been halted by IIROC:
IIROC Trade Resumption - RVX
TORONTO, May 15, 2019 /CNW/ - Trading resumes in:
Resverlogix Announces Pricing of Unit Offering
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has priced its previously announced marketed offering (the "Offering") of units of the Company (the "Units") at $4.00 per Unit. Each Unit consists...
IIROC Trading Halt - RVX
TORONTO, May 15, 2019 /CNW/ - The following issues have been halted by IIROC:
Resverlogix Announces Proposed Offering of Units
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed a preliminary short form prospectus with the securities regulatory authorities in the provinces of Ontario, Alberta and British Columbia in connection...
Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: "Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension" in the...
Resverlogix Announces 3-Month Loan Extension
Resverlogix' BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announces that BETonMACE, the Company's event-based, phase 3 registration trial has successfully reached 250 projected major adverse cardiac events (MACE), strictly defined as...
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer's & Parkinson's Diseases
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announces that Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center, Las Vegas, Nevada, gave an oral presentation this past weekend at the...
Resverlogix Announces $15.1 Million of Private Placements
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed private placements of approximately 4.5 million equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. ("Hepalink") and 0.6 million equity units to other...
Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announces the independent Data and Safety Monitoring Board (DSMB) has completed a ninth planned safety review for the Company's Phase 3, BETonMACE trial for high-risk cardiovascular...
Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the advancement of a $2.9 million project led by academic collaborators at Quebec Heart and Lung Institute, Laval University, to research the clinical potential of its...
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a wholly-owned subsidiary of Zenith Capital Corp., announced today that the U.S. Food and Drug Administration ("FDA") has cleared the Company's investigational new drug application for ZEN-3694,...
Resverlogix Announces Participation at Prominent Industry and Investor Conferences
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading industry and investor conferences during the month of March including, the American College of Cardiology's (ACC) 68th Annual Scientific...
Resverlogix Closes $6.6 Million Private Placement with Shenzhen Hepalink
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of approximately 2.2 million equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. ("Hepalink") at a price of $3.00 per unit for...
Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announces the independent Data and Safety Monitoring Board (DSMB) has completed an eighth planned safety review for the Company's Phase 3, BETonMACE trial for high-risk...
Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: "Apabetalone downregulates factors and pathways associated with vascular calcification" in Atherosclerosis, the official...
Resverlogix Closes $13.5 Million Private Placement
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of approximately 4.5 million equity units at a price of $3.00 per unit for gross proceeds of approximately $13.5 million (US$10.3...
Resverlogix Announces Participation at Premier Kidney, Alzheimer's Disease and Cardiovascular Conferences
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at premier conferences including the American Society of Nephrology (ASN) Kidney Week 2018, Clinical Trials on Alzheimer's Disease (CTAD) 2018 and the...
Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders
Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the "Meeting") in Calgary, Alberta. A total of 126,864,830 shares (approximately 71.50% of outstanding common shares) were...
Resverlogix Presents at Clinical Trials in Alzheimer's Disease (CTAD) Asia 2018
As a follow up to its July 17, 2018 news release, Resverlogix Corp. ("Resverlogix" or the "Company") (RVX:TSX) announced today that it has presented at the first Clinical Trials in Alzheimer's Disease (CTAD) Asia conference in Shanghai, China, this...
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of approximately 10.4 million equity units at a price of $2.50 per unit for gross proceeds of approximately $26 million (US$20 million),...
Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced it is supporting a satellite symposium on August 25th, 2018, at the European Society of Cardiology Congress 2018 in Munich, Germany, titled: LDL-c: Done Deal, Next...
Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 BETonMACE trial in high-risk cardiovascular disease (CVD) patients has completed a...
Resverlogix Intends to Pursue U.S. Listing
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it intends to pursue a listing of its common shares in the United States. Accordingly, if necessary in order to comply with stock exchange minimum share price...
Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer's Disease (CTAD) Asia and Alzheimer's Association International Conference (AAIC)
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has been awarded two presentations at the Clinical Trials in Alzheimer's Disease (CTAD) Asia conference in Shanghai, China. Dr. Jeffrey Cummings, Founding Director...
Hemostemix Formalizes World-Class Scientific Advisory Board
Hemostemix Inc. ("Hemostemix" or the "Company") (TSX-V:HEM) is pleased to announce the formalization of its Scientific Advisory Board ("SAB"). Members of the SAB are all leaders in their fields of expertise, which span biochemistry, molecular...
Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has received confirmation from the U.S. Food and Drug Administration ("FDA") that BETonMACE, Resverlogix's on-going Phase 3 study, if successful, is likely to...
Resverlogix Announces Withdrawal of Public Offering of Units
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has opted not to proceed with the public offering of units of the Company announced on April 17, 2018, based on the Company's assessment that market conditions are...
Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the "Shock and Kill" Approach
Based on recent findings on apabetalone's potential role in human immunodeficiency virus ("HIV-1") eradication, Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is seeking a partnership with an existing stakeholder in the ongoing fight...
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is...
Resverlogix Announces Lifting by TSX of Review
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that, following the previously announced review, the Continued Listing Committee of Toronto Stock Exchange ("TSX") has determined that the Company satisfies TSX's...
Resverlogix Closes US$30 Million Loan
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed the previously announced US$30 million senior secured loan (the "Loan") with Third Eye Capital. The net proceeds of the Loan will be used to fund...
Resverlogix Advances US$30 Million Loan Closing Documentation
CALGARY, Alberta, May 01, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to update the market today that it is in the final stages of closing documentation in respect of the previously-announced US$30...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Resverlogix Announces TSX Review Update
CALGARY, Alberta, April 12, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has received a 30-day extension to no later than May 14, 2018 for the TSX's review of the Company's compliance...
Resverlogix Announces US$30 Million Loan Commitment Letter
Resverlogix also Announces the Closing of $3.2 Million in Equity Financing
Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
CALGARY, Alberta, March 28, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the publication of two new articles on the effect of apabetalone, a novel small molecule BET (bromodomain and extra-terminal) inhibitor, in...
Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial
The BETonMACE trial has now surpassed 2,400 enrolled patients and topline data is expected around the end of 2018
Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without any modification
Resverlogix Highlights Key Accomplishments and 2018 Targets
CALGARY, Alberta, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) highlighted today recent key accomplishments and 2018 targets.
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
Patient enrollment in the United States is expected to commence this quarter
Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement
Alliance to focus on regulatory approval, commercialization and marketing of novel apabetalone therapy in Israel
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
CALGARY, Alberta, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended October 31,...
CALGARY, Alberta, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX:RVX) announced today that, at its annual meeting of shareholders held on December 12, 2017, Resverlogix shareholders approved all resolutions outlined in the Notice...
Nature's Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1
CALGARY, Alberta, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that a recent Nature Scientific Reports has published a 12 page publication on BET (bromodomain and extra-terminal) inhibitors; RVX-208 (apabetalone) and...
Resverlogix Repays $68.8 Million Loan
CALGARY, Alberta, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has repaid, in full, its CAD$68.8 million Loan (the "Loan"). Upon repayment of the Loan, the Company has no...
Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
CALGARY, Alberta, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed its previously announced private placement of 60,416,667 equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. ("Hepalink") at...
Resverlogix Announces Participation in Upcoming Conferences
CALGARY, Alberta, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the Company's participation in the following upcoming industry conferences.
Resverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Resverlogix Announces Right of First Refusal Agreement with Hepalink USA Inc.
CALGARY, Alberta, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced that it has entered into a Right of First Refusal Agreement (the "Agreement") with Hepalink USA Inc. ("Hepalink USA"). Under the Agreement, Hepalink USA was granted a right of first refusal in connection with the licensing of the right to develop, manufacture and commercialize pharmaceutical products containing RVX-208 (apabetalone) in the United States (the "US Licensing Rights") until April 15, 2019. Hepalink USA paid $8 million (the "Fee") to Resverlogix in considerat...
TORONTO, Oct. 13, 2017 /CNW/ - Trading resumes in:
TORONTO, Oct. 13, 2017 /CNW/ - The following issues have been halted by IIROC:
IIROC Trade Resumption - Resverlogix Corp.
Toronto, Ontario--(Newsfile Corp. - October 13, 2017) - Trading resumes in:
IIROC Trade Halt - Resverlogix Corp.
Toronto, Ontario--(Newsfile Corp. - October 13, 2017) - The following issues have been halted by IIROC:
CALGARY, Alberta, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that its Annual and Special Meeting of Shareholders (the "Meeting") is to be held Tuesday, December 12, 2017 at Mount Royal University, Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta, commencing at 1:00 pm (MT)....
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
CALGARY, Sept. 13, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended July 31, 2017 and related Management's Discussion and Analysis with Canadian securities regulatory authorities.
CALGARY, Sept. 13, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended July 31, 2017 and related Management's Discussion and Analysis with Canadian securities regulatory authorities.
Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
CALGARY, Sept. 5, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed the previously announced extension of the Company's loan. The maturity date of the $68.8 million loan has been extended to December 26, 2017 on the terms and conditions that were announced on August 28, 2017.
CALGARY, Sept. 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed the previously announced extension of the Company's loan. The maturity date of the $68.8 million loan has been extended to December 26, 2017 on the terms and conditions that were announced on August 28, 2017.
Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
CALGARY, Aug. 29, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that key findings from the recently completed CANTOS trial, which demonstrate that targeting residual inflammatory risk resulted in a reduction in the incidence of Major Adverse Cardiovascular Events ("MACE"), validate the importance of reducing inflammation as a therapeutic strategy for treating Cardiovascular Disease ("CVD").
CALGARY, Aug. 29, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that key findings from the recently completed CANTOS trial, which demonstrate that targeting residual inflammatory risk resulted in a reduction in the incidence of Major Adverse Cardiovascular Events ("MACE"), validate the importance of reducing inflammation as a therapeutic strategy for treating Cardiovascular Disease ("CVD").
Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
CALGARY, Aug. 28, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the following update on its corporate activities.
CALGARY, Aug. 28, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the following update on its corporate activities.
Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
CALGARY, July 25, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it filed its audited Consolidated Financial Statements for the year ended April 30, 2017 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. The Company has also filed its Annual Information Form for the year ended April 30, 2017. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing [email protected] An additional corporate financial update will take place pr
CALGARY, July 25, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it filed its audited Consolidated Financial Statements for the year ended April 30, 2017 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. The Company has also filed its Annual Information Form for the year ended April 30, 2017. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing [email protected] An additional corporate financial update will take p
TORONTO, July 25, 2017 /CNW/ - Trading resumes in:
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
"BETonMACE Phase 3 Trial with apabetalone to expand to include the United States"
TORONTO, July 25, 2017 /CNW/ - The following issues have been halted by IIROC:
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
CALGARY, July 10, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the first patient has been randomized in Taiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular disease ("CVD") and type 2 diabetes mellitus ("DM").
CALGARY, July 10, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the first patient has been randomized in Taiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular disease ("CVD") and type 2 diabetes mellitus ("DM").
The Life Sciences Report Examines How With Completion of Offer, Analyst Says This Biotech Stock Could Triple
A Canadian company with its lead drug candidate in a Phase 3 trial recently closed an offering that raised CA$10 million for future research, which has one analyst contemplating the potential.Included in this article is: Resverlogix Corp. (TSX:...
Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without any modification.
Resverlogix Comments on TSX Trader Notes
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Resverlogix Closes $10 Million of Equity Subscriptions
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATIONIN THE UNITED STATES/
Resverlogix to Raise Up To $10 Million
Resverlogix Announces Overnight Marketed Equity Offering
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
CALGARY, June 5, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that a recently submitted paper titled: "Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)" was published in the Journal of Cardiovascular Translational Research. The Company also provided details of its upcoming participation in an upcoming industry conference.
CALGARY, June 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that a recently submitted paper titled: "Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)" was published in the Journal of Cardiovascular Translational Research. The Company also provided details of its upcoming participation in an upcoming industry conference.
Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain
The symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress highlights BET-inhibition and apabetalone in addressing the significant unmet medical need in chronic kidney disease and cardiovascular disease.
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
Apabetalone expands in to first orphan disease clinical trial in patients with Fabry disease
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
Nature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates
Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
Apabetalone expands to a second major clinical indication in kidney dialysis patients
Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
CALGARY, March 15, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the use of apabetalone in combination with Rosuvastatin in the United States. Rosuvastatin was exclusively marketed by AstraZeneca under the trade name Crestor® until its patent expired in 2016. The allowed patent is entitled: "Compositions and Therapeutic Methods for Accelerated Plaque Regression," and covers claims for both a single composition as well as separ
CALGARY, March 15, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the use of apabetalone in combination with Rosuvastatin in the United States. Rosuvastatin was exclusively marketed by AstraZeneca under the trade name Crestor® until its patent expired in 2016. The allowed patent is entitled: "Compositions and Therapeutic Methods for Accelerated Plaque Regression," and covers claims for both a single composition as well a
Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
Protocol comments and recommendations incorporated
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
Emergence of new potential indications for apabetalone (RVX-208) via third party research
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
Several Key Proteins That Drive Kidney (Renal) Disease and Dialysis Risk are Downregulated After a Single Dose of Apabetalone
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA
CALGARY, Jan. 5, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) today announces its participation in the 9th Annual Biotech Showcase Conference during J.P. Morgan week in San Francisco, CA. Mr. Donald J. McCaffrey, President and CEO, will provide a corporate update and overview of recent activities at the conference.
CALGARY, Jan. 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) today announces its participation in the 9th Annual Biotech Showcase Conference during J.P. Morgan week in San Francisco, CA. Mr. Donald J. McCaffrey, President and CEO, will provide a corporate update and overview of recent activities at the conference.
CALGARY, Dec. 15, 2016 /CNW/ - Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX: RVX) today announced that, at its annual and special meeting of shareholders held on December 15, 2016, Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 3, 2016 (the "Information Circular"), which is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.
CALGARY, Dec. 15, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX: RVX) today announced that, at its annual and special meeting of shareholders held on December 15, 2016, Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 3, 2016 (the "Information Circular"), which is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.
CALGARY, Dec. 13, 2016 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended October 31, 2016 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing [email protected]
CALGARY, Dec. 13, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended October 31, 2016 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing [email protected]
Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies
The successful completion of this Phase 1 pharmacokinetic (PK) trial in patients with severe renal impairment clears the path for the Company to further expand its previously announced Renal and Orphan programs


text:
Live DJ: Wayne Lango FREE
http://livebrum.co.uk/the-sun-on-the-hill/2018/09/14/live-dj-wayne-lango
Source http://thesunonthehill.co.uk/events/category/party
Friday 14 8.30PMSeptember2018-09-14T20:30:00Z2018-09-14T22:20:00Z
http://livebrum.co.uk/venues/the-sun-on-the-hill
23 Bennetts Hill
B2 5QP Birmingham GB
Subscribe to all events at The Sun on the Hill
Subscribe to all Club events
Subscribe to all Club events at The Sun on the Hill
Subscribe to all events on Fri 14 September 2018
Upcoming at The Sun on the Hill view all
Early Doors 6:30pm
2 Aug, 6.30pm
View all events at The Sun on the Hill
Other events on 14 Sep 2018 view all
Heritage Week: Reclaiming Our Future 6 Sep 2018 - 16 Sep 2018
6 Sep 2018 - 16 Sep 2018
The 39 Steps 8 Sep 2018 - 15 Sep 2018
Heritage Week: Tour of The New Standard Works 10 Sep 2018 - 15 Sep 2018
Community at The Hive Heritage Hub
Heritage Week: Cadbury World Heritage Talks and Tours 10 Sep 2018 - 14 Sep 2018
Absent Friends 11 Sep 2018 - 22 Sep 2018
Theatre at Highbury Theatre Centre
Taj Express 11 Sep 2018 - 15 Sep 2018
Dance at Birmingham Hippodrome
Pop Music 12 Sep 2018 - 22 Sep 2018
Heritage Week: Open Church 13 Sep 2018 - 16 Sep 2018
Community at St Alban's Church
Faulty Towers: The Dining Experience 13 Sep 2018 - 15 Sep 2018
League of Gentlemen 13 Sep 2018 - 14 Sep 2018
Theatre at Arena Birmingham
The Art & Science of Reading People 9:30am
14 Sep 2018, 9.30am
Workshop at Garden House
Discover Your South Africa 14 Sep 2018 - 16 Sep 2018
Heritage Week: St Mary's Convent 14 Sep 2018 - 16 Sep 2018
Community at St Mary's Convent
Heritage Week: Kingswood Unitarian Chapel 14 Sep 2018 - 15 Sep 2018
Community at Kingswood Unitarian Chapel
Study Days: The Merry Wives of Windsor, Troilus & Cressida 10:15am
14 Sep 2018, 10.15am
Spoken Word at Birmingham and Midland Institute
Nature Tots 10:30am
Anna the Art Explorer 10:30am
Drama Adventures with Toni Midlane 10:30am

redpajama_set_name: RedPajamaCommonCrawl


text:
using System;
using System.Runtime.CompilerServices;
using SQLite;

namespace Xamarin.Codebase.DataAccess.Interfaces
{
    public interface IDbContext
    {
        SQLiteConnection Db { get; }

        void RunDbOperation(
            Action action,
            bool inTransaction = true,
            [CallerMemberName] string caller = null);

        TRes RunDbOperation<TRes>(
            Func<TRes> func,
            bool inTransaction = true,
            [CallerMemberName] string caller = null);
    }
}

redpajama_set_name: RedPajamaGithub


The Broad-tailed Hummingbird (Selasphorus platycercus) is considered to be the most common hummingbird nesting in the Rocky Mountains and will be found in good numbers north to Wyoming and Idaho. They are very early migrants in the spring and don't seem to mind arriving before the snow has melted away. The species name means "broad tail" in Greek. KEY CHARACTERISTICS The Broad-tailed is a medium sized hummingbird with a long tail and a medium long straight black bill. The adult male has a brilliant gorget shading from hot pink to rose red, contrasting with a white breast. DISTRIBUTION Breeds from Wyoming and central Idaho south all the way to Guatemala. Any Broad-tailed spotted outside of Wyoming, Idaho, Nevada, Utah, Colorado, Arizona, and New Mexico should be considered lost and provided a map to return home. Vagrants have been spotted from California north to British Columbia, Texas north to South Dakota and as far east as Indiana and Georgia.
The Calliope Hummingbird (Stellula calliope) is the smallest of all hummingbirds that breed in the U.S. in fact an adult weighs about the same as a penny! They are nearly silent which is ironic because their species name in Greek means "beautiful voice". KEY CHARACTERISTICS The Calliope Hummingbird is very small with a very short tail and a short black bill. The adult male has a gorget that consists of red to reddish-purple streaks over a white background which is very unique. DISTRIBUTION Breeds primarily in the higher elevations from northern Baja California north to south eastern British Columbia, east to western Montana and western Wyoming. While definitely concentrated in the Northwest, vagrants have been spotted in much of the central U.S. as well as the Southeast.


text:
NPNF (V2-02)
« Prev Severian, Bishop of Gabales, and Antiochus,… Next »
Chapter X.—Severian, Bishop of Gabales, and Antiochus, Bishop of Ptolemaïs. Dispute between Serapion and Severian. Reconciliation between them effected by the Empress.
John likewise incurred the enmity of the empress, through the machinations of Severian, bishop of Gabali in Syria.15961596 Soc. vi. 11; Pallad. Dialog. Severian and Antiochus, bishop of Ptolemaïs, a city in Phœnicia, were both learned men, and well qualified to teach in the churches. Antiochus had so fine a voice and delivery that, by some persons, he was surnamed Chrysostom. Severian, on the other hand, had the harshness of the Syrians in his speech; but, in point of knowledge and the evidences of the Scriptures, he was considered superior to Antiochus. It appears that Antiochus was the first to visit Constantinople; he gained great applause by his discourses, amassed some property, and then returned to his own city. Severian followed his example, and went to Constantinople. He formed an intimacy with John, spoke frequently in the churches, and was admired. He was in honor, and became well known to many of those in power, and to the emperor and empress. When John went to Asia, he commended the Church to his care; for he was so far deceived by the adulation of Severian as to imagine him to be his zealous friend. Severian, however, thought only of gratifying his auditors, and of pleasing the people by his discourses.15971597 A number of the homilies still attributed to Chrysostom, as well as those now acknowledged not to be his, were from the eloquent Severian. When John was apprised of this, he was filled with jealousy; and his resentment was further kindled, it is said, by the representations of Serapion. After the return of John from Asia, Serapion happened to see Severian passing; but, instead of rising to salute him, he kept his seat, in order to show his utter contempt for the man. Severian was offended by this manifestation of disrespect, and exclaimed, "If Serapion die a clergyman, then Christ was not incarnate." Serapion reported these words; and John, in consequence, expelled Severian from the city as insolent, and as a blaspheme against God; for witnesses were brought forward to attest that the above words had been really uttered by him. Some of the friends of Serapion even went so far as to suppress part of the speech of Severian, and to affirm that he had declared that Christ was not incarnate. John also rebuked Severian, by asking whether, "If Serapion should not die among the clergy, it would follow that Christ had not been incarnate?" As soon as the wife of the emperor was informed by the friends of Severian of what had occurred, she immediately sent for him from Chalcedon. John, notwithstanding all her remonstrances, positively refused to hold any intercourse with him, until the empress placed her son Theodosius on his knees in the church named after the apostles; then she entreated him persistently, and frequently adjured him, until John yielded a reluctant consent to receive Severian into friendship. Such are the accounts which I have received of these transactions.15981598 Chrys. Homilia de recipiendo Severiano; andSermo ipsius Severiam de pace, iii. 421–423.
1596 Soc. vi. 11; Pallad. Dialog.
1597 A number of the homilies still attributed to Chrysostom, as well as those now acknowledged not to be his, were from the eloquent Severian.
1598 Chrys. Homilia de recipiendo Severiano; andSermo ipsius Severiam de pace, iii. 421–423.